Month: August 2024

Cancer-related anemia (CRA) encompasses anemia that occurs in cancer patients during disease progression or treatment, including non-chemotherapy-related CRA and chemotherapy-induced anemia (CIA). With the increase in chemotherapy treatments, the incidence of anemia is significant, with over 90% of patients not receiving any corrective treatment. To gain a comprehensive understanding of the current practices and perceptions of Chinese clinicians in managing CIA and to improve the management level of CIA in China, Oncology Frontier initiated a "Survey on Chemotherapy-Induced Anemia in Cancer Patients," collecting 308 questionnaires from 28 provinces and cities across the country. The survey revealed that although the current management concepts of CIA in China still differ from existing guidelines, Chinese clinicians' awareness of CIA management is continually strengthening, contributing to the standardization of management for anemia related to new anti-cancer therapies.

Mammography is the only imaging method proven to detect breast cancer early and reduce patient mortality; however, traditional mammography often yields false-positive results, and the long-term outcomes of these false positives remain unclear. Recently, a Swedish study involving 497,343 women found that the risk of breast cancer following a false-positive mammogram varies based on personal characteristics and follow-up. These findings underscore the importance of long-term follow-up awareness for women with false-positive mammograms and help tailor personalized screening strategies based on false-positive results.

On July 27-28, 2024, the "2024 Breast Cancer Summer Forum·Northern Salon" was grandly held at the Shougang Park in Beijing. The conference adhered to the concept of "learning, absorbing, innovating, and improving" and embraced the tradition of "All directions, Throughout time and across the world, Across all seasons, People of all ages and genders" offering an academic feast in the midsummer. In the era of immunotherapy, triple-negative breast cancer (TNBC) has broken through bottlenecks, achieving survival benefits in both short-term and long-term efficacy. After the TNBC session, Dr. Cuizhi Geng from The Fourth Hospital of Hebei Medical University, Dr. Haibo Wang from The First Clinical Medical College of Qingdao University, Dr. Tao Wang from the Chinese PLA General Hospital, and Dr. Kun Wang from the Guangdong Provincial People's Hospital discussed the present and future of TNBC immunotherapy, guiding the development of precision and individualized immunotherapy.

Prostate cancer is a common malignant tumor of the reproductive system, particularly affecting elderly men. Screening high-risk populations and tailoring treatment plans based on patient characteristics are crucial for improving cure rates and enhancing quality of life. Recently, the 2024 ASCO Annual Meeting unveiled numerous advancements in the treatment of prostate cancer. "Oncology Frontier" invited Dr. Fu Fu Zheng from The First Affiliated Hospital , Sun Yat-sen University to provide an in-depth analysis of these advancements and discuss the latest breakthroughs in prostate cancer. This article summarizes notable real-world research explorations and related poster presentations for readers.

Prostate cancer is a common malignant tumor of the reproductive system, particularly affecting elderly men. Screening high-risk populations and tailoring treatment plans based on patient characteristics are crucial for improving cure rates and enhancing quality of life. Recently, the 2024 ASCO Annual Meeting unveiled numerous advancements in the treatment of prostate cancer. "Oncology Frontier" invited Dr. Fu Fu Zheng from The First Affiliated Hospital , Sun Yat-sen University to provide an in-depth analysis of these advancements and discuss the latest breakthroughs in prostate cancer. This article summarizes notable real-world research explorations and related poster presentations for readers.

In the field of breast cancer treatment, innovative therapies are emerging constantly, yet many issues still urgently need to be addressed. Recently, Academician Binghe Xu and Dr. Fei Ma from the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College published an article in Nature Medicine titled "Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial." The study introduces the latest progress in metronomic chemotherapy combined with immunotherapy in breast cancer. This research not only provides a new treatment option for breast cancer patients but also reveals the synergistic potential of metronomic chemotherapy and immunotherapy. At the Seventh Tumor Precision Diagnosis and Treatment Conference and the Tenth Breast Cancer Individualized Treatment Conference (2024 COMB), Oncology Frontier invited Dr. Fei Ma to discuss the current state of breast cancer treatment and his team's related articles.